ACC Previews Next Round Of Stent Wars: Ease-Of-Use Claims Will Be Key

The singular U.S. market dominance of the cobalt-chromium everolimus-eluting stent known as Xience V or Promus is likely to be threatened next year as two new next-generation products make their way to market.